Trial Profile
An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Phase III, Randomized, Controlled Study Comparing the Efficacy and Safety of mFOLFOX6 + Bevacizumab Therapy vs. mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Wild-type RAS(KRAS/NRAS) Unresectable Advanced or Recurrent Colorectal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2023
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Bevacizumab; Fluorouracil; Levofolinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms PARADIGM
- Sponsors Takeda
- 04 Dec 2023 Planned End Date changed from 31 Mar 2024 to 31 Mar 2025.
- 04 Dec 2023 Planned primary completion date changed from 31 Mar 2024 to 31 Mar 2025.
- 26 May 2023 According to a Takeda media release, data from this trial will be presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2023.